AN2 Therapeutics
ANTX
38 hedge funds and large institutions have $94.8M invested in AN2 Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
6% more funds holding
Funds holding: 36 → 38 (+2)
2% more capital invested
Capital invested by funds: $92.9M → $94.8M (+$1.82M)
0.84% less ownership
Funds ownership: 50.32% → 49.49% (-0.84%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$584K |
| 2 |
BlackRock
New York
|
+$425K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$243K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$139K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.25M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.02M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$227K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$52.1K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$12.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
New York State Common Retirement Fund
Albany,
New York
| $58K | +$600 | +54 | +0.9% |
|
|
AIG
27
American International Group
New York
| $52.9K | +$1.19K | +107 | +2% |
|
28
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| $40.8K | -$3.39K | -305 | -7% |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $28K | +$21.6K | +1,941 | +227% |
|
|
SO
30
STRS Ohio
Columbus,
Ohio
| $22K | – | – | – |
|
31
Wells Fargo
San Francisco,
California
| $19.4K | +$21.9K | +1,966 | New |
|
|
AB
32
Amalgamated Bank
New York
| $17K | -$945 | -85 | -5% |
|
33
Legal & General Group
London,
United Kingdom
| $11.6K | – | – | – |
|
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| $6K | -$12.3K | -1,109 | -63% |
|
|
AIP
35
Ameritas Investment Partners
Lincoln,
Nebraska
| $3.44K | – | – | – |
|
36
Fidelity Investments
Boston,
Massachusetts
| $3.03K | +$623 | +56 | +22% |
|
37
Osaic Holdings
Scottsdale,
Arizona
| $1.97K | – | – | – |
|
|
WP
38
Woodline Partners
San Francisco,
California
| – | -$1.02M | -107,300 | Closed |
|
ANTX Hedge Fund Activity: Q1 2023 in Review
38 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q1 2023, worth a combined $94.8M — up 2% from $92.9M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ANTX positions and 1 closed out — a net gain of 2 holders — while 20 added to existing stakes and 7 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $584K. The largest seller was Monashee Investment Management, cutting an estimated $2.25M.
- 38 institutional investors held AN2 Therapeutics (ANTX) as of Q1 2023, up from 36 in Q4 2022.
- Funds reported $94.8M of AN2 Therapeutics stock for Q1 2023, up 2% quarter-over-quarter.
- 3 funds opened new AN2 Therapeutics positions in Q1 2023 and 1 closed out, a net change of +2 holders.
- The largest AN2 Therapeutics buyer in Q1 2023 was Bridgeway Capital Management, an estimated $584K added.
- The largest AN2 Therapeutics seller in Q1 2023 was Monashee Investment Management, an estimated $2.25M sold.
Based on aggregated 13F filings for Q1 2023.